Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients
Authors
Keywords
-
Journal
POSTGRADUATE MEDICINE
Volume -, Issue -, Pages 1-11
Publisher
Informa UK Limited
Online
2020-08-20
DOI
10.1080/00325481.2020.1800286
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
- (2020) Mansoor Husain et al. DIABETES OBESITY & METABOLISM
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2020 EXECUTIVE SUMMARY
- (2020) Alan J. Garber et al. Endocrine Practice
- 932-P: Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program
- (2020) VANITA R. ARODA et al. DIABETES
- Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
- (2020) Stephen A. Brunton et al. POSTGRADUATE MEDICINE
- GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
- (2020) Stephen A. Brunton et al. POSTGRADUATE MEDICINE
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea
- (2019) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features
- (2019) Katherine A. Lyseng-Williamson CLINICAL DRUG INVESTIGATION
- 1013-P: Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects with Type 2 Diabetes
- (2019) JURIS J. MEIER et al. DIABETES
- PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
- (2019) Vanita R. Aroda et al. DIABETES CARE
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
- (2019) Richard Pratley et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis
- (2019) Yufang Liu et al. Journal of Diabetes Research
- Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
- (2019) Thomas R Pieber et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
- (2019) Bernard Zinman et al. DIABETES CARE
- Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
- (2019) Helena W. Rodbard et al. DIABETES CARE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- 12. Older Adults: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- The global burden of kidney disease and the sustainable development goals
- (2018) Valerie A Luyckx et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
- (2018) Charlotte Granhall et al. CLINICAL PHARMACOKINETICS
- Economic Costs of Diabetes in the U.S. in 2017
- (2018) DIABETES CARE
- Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
- (2018) Tine A. Baekdal et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data
- (2018) Edward W Gregg et al. LANCET
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- Global trends in diabetes complications: a review of current evidence
- (2018) Jessica L. Harding et al. DIABETOLOGIA
- Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
- (2018) Stephen C. Bain et al. DIABETES OBESITY & METABOLISM
- Response to Comment on Crews et al. Role and Determinants of Adherence to Off-loading in Diabetic Foot Ulcer Healing: A Prospective Investigation. Diabetes Care 2016;39:1371–1377
- (2016) Ryan T. Crews et al. DIABETES CARE
- Up front
- (2016) DIABETOLOGIA
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Normoalbuminuric renal impairment and all-cause mortality in type 2 diabetes mellitus
- (2014) Salvatore De Cosmo et al. ACTA DIABETOLOGICA
- DPP-4 inhibitors: focus on safety
- (2014) Sri Harsha Tella et al. Expert Opinion On Drug Safety
- All-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large U.K. Primary Care Database
- (2013) K. S. Taylor et al. DIABETES CARE
- Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
- (2013) E. R. Seaquist et al. DIABETES CARE
- Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes
- (2013) Yujie Wang et al. KIDNEY INTERNATIONAL
- Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts
- (2011) Ron T. Gansevoort et al. KIDNEY INTERNATIONAL
- Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts
- (2011) Brad C. Astor et al. KIDNEY INTERNATIONAL
- Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication
- (2010) Marco DiBonaventura et al. Patient Preference and Adherence
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search